Albert Ong

Albert brings the enormous experience in the molecular, cellular and clinical aspects of Autosomal Dominant Polycystic Kidney Disease (ADPKD) to aid Mironid’s ongoing efforts to develop selective activators of phosphodiesterase-4 (PDE4) long isoforms for the treatment of ADPKD. Albert is Co-chair of the ADPKD in Europe Consortium; Vice-Chair of the UK Kidney Research Consortium (UKKRC) Clinical Study Group on Cystic Kidney Diseases; former Chair of the Renal Association International Committee and Faculty member of the European ADPKD Forum. He is also an external faculty member of the Mayo Translational PKD Centre and was a nominated clinical expert for the National Institute for Clinical Excellence (NICE) Technology Appraisal of Tolvaptan for ADPKD.